PRIME POLICY GROUP

Lobbying for KEDRION BIOPHARMA · Production of Plasma-Derived Therapies

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · New Jersey · House · Senate · $140,000.00 income · posted Jan 15, 2026

Lobbying activity 1

Trade (domestic/foreign)

Pharmaceutical tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem